Roche announced a definitive merger agreement to acquire PathAI, a U.S.-based digital pathology and AI diagnostics company, in a transaction valued at up to $1.05 billion. Under the terms of the agreement, Roche will pay $750 million upfront with an additional $300 million tied to milestone payments. The transaction is expected to close during the second half of the year, subject to customary regulatory and antitrust approvals.
The acquisition expands Roche’s digital pathology and AI-driven diagnostics capabilities by integrating PathAI’s Image Management System platform, AISight, into Roche Diagnostics.
Roche said PathAI’s software platform combines image management, AI analysis, and pathology workflow capabilities designed to improve laboratory efficiency and accelerate diagnostic processes.
The companies previously established a partnership in 2021 that expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.
Roche said the acquisition strengthens its position in digital pathology, which uses high-resolution digital imaging and AI analysis to support cancer diagnosis and treatment selection workflows.
The company also noted that combining Roche’s companion diagnostics expertise with PathAI’s AI capabilities could accelerate biomarker discovery, translational research, clinical trial support, and personalized medicine development for biopharma customers.
PathAI focuses on AI-powered pathology technologies for laboratories and pharmaceutical companies, while Roche operates global diagnostics and pharmaceutical businesses across oncology, neurology, immunology, infectious disease, and other therapeutic areas.
KEY QUOTES:
“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens. Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”
Matt Sause, CEO, Roche Diagnostics
“Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed. Roche’s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.”
Andy Beck, CEO And Co-Founder, PathAI
